Weill Cornell Medicine
New York, 10065, United States
NCT Number: NCT05136092
This proposed study is designed to investigate the specific uptake of fructose by human colorectal tumors. In this study, subjects with colorectal cancer undergoing surgery will receive an oral sugar solution containing fructose or xylose prior to surgery. The tumor will then be resected, and a portion of the tissue will be used to measure the abundance of fructose and xylose. The study hypothesis is that the tumors will take up fructose sugar but not xylose sugar. A comparison of the sugar uptake between the tumor and normal tissues from the adjacent intestinal epithelium and smooth muscle and the liver will be conducted. This proposal will confirm that human colorectal cancer tumors can directly absorb dietary sugars, which has never been demonstrated.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
New York, 10065, United States
This prospective pilot study is designed to investigate the uptake of dietary fructose and xylose by primary human colon tumors. In this study, the recruited patients with colorectal cancer will receive an oral sugar solution containing either Fructose sugar or Xylose sugar before surgery. The tumor will then be resected and a portion of the tumor, normal intestinal tissue, blood, urine, and liver will be used to quantify fructose and xylose.
N=12 Subjects Cohort 1: Fructose sugar solution =6 Subjects Cohort 2: Xylose sugar solution=6 Subjects
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Two to three hours before surgery. Subjects will prepare the sugar solutions (Fructose-containing solution: 250 mL of water containing 41.25 g of D-Fructose and 33.75 g of D-Glucose) by adding 250 ml water to the sugar powder provided by the study team and drink it between two and three hours before surgery.
Samples collected before surgery:
Day of Surgery The anesthesia and surgical procedure will undergo as per regular care. Samples collection at the time the surgical specimen is removed
Two to three hours before surgery.
Subjects will prepare the sugar solutions (Xylose-containing solution: 250 mL of water containing 41.25 g of D-Xylose and 33.75g of D-Glucose) by adding 250 ml water to the sugar powder provided by the study team and drink it between two and three hours before surgery.
Samples collected before surgery:
Day of Surgery The anesthesia and surgical procedure will undergo as per regular care. Samples collection at the time the surgical specimen is removed
Time frame: Morning after the consumption of oral sugar solutions(during surgery at the time of specimen removal)
The abundance of fructose in tumor extracts assessed by mass spectrometry in the morning after the consumption of oral sugar solutions.
Time frame: Morning after the consumption of oral sugar solutions(during surgery at the time of specimen removal)
The abundance of Fructose and [13C]-Fructose in the blood in the morning after the consumption of oral sugar solutions assessed by mass spectrometry.
Time frame: Morning after the consumption of oral sugar solutions(during surgery at the time of specimen removal)
The abundance of Fructose and [13C]-Fructose in the urine in the morning after the consumption of oral sugar solutions assessed by mass spectrometry.
Time frame: Morning after the consumption of oral sugar solutions(during surgery at the time of specimen removal)
The abundance of Fructose and [13C]-Fructose in the liver tissue in the morning after the consumption of oral sugar solutions assessed by mass spectrometry.
Time frame: Morning after the consumption of oral sugar solutions(during surgery at the time of specimen removal)
The abundance of Fructose and [13C]-Fructose in the intestine tissue in the morning after the consumption of oral sugar solutions assessed by mass spectrometry.
Time frame: Morning after the consumption of oral sugar solutions(during surgery at the time of specimen removal)
The abundance of Fructose and [13C]-Fructose in the mesentery tissue in the morning after the consumption of oral sugar solutions assessed by mass spectrometry.
Time frame: Morning after the consumption of oral sugar solutions(during surgery at the time of specimen removal)
The abundance of Xylose and [13C]-Xylose in the blood in the morning after the consumption of oral sugar solutions assessed by mass spectrometry.
Time frame: Morning after the consumption of oral sugar solutions(during surgery at the time of specimen removal)
The abundance of Xylose and [13C]-Xylose in the urine in the morning after the consumption of oral sugar solutions assessed by mass spectrometry.
Time frame: Morning after the consumption of oral sugar solutions(during surgery at the time of specimen removal)
The abundance of Xylose and [13C]-Xylose in the liver tissue in the morning after the consumption of oral sugar solutions assessed by mass spectrometry.
Time frame: Morning after the consumption of oral sugar solutions(during surgery at the time of specimen removal)
The abundance of Xylose and [13C]-Xylose in the intestinal tissue in the morning after the consumption of oral sugar solutions assessed by mass spectrometry.
Time frame: Morning after the consumption of oral sugar solutions(during surgery at the time of specimen removal)
The abundance of Xylose and [13C]-Xylose in the mesentery tissues in the morning after the consumption of oral sugar solutions assessed by mass spectrometry.
Time frame: Morning after the consumption of oral sugar solutions(during surgery at the time of specimen removal)
The abundance of Xylose and [13C]-Xylose in the tumor in the morning after the consumption of oral sugar solutions assessed by mass spectrometry.
Weill Medical College of Cornell University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03377361
Colonic Diseases, Colorectal Cancer
Birmingham, Alabama, United States
View Trial DetailsNCT03428958
Colonic Diseases, Colonic Neoplasms
Boston, Massachusetts, United States
View Trial DetailsNCT01291420
Adenocarcinoma, Adenoma
Edegem, Antwerp, Belgium
View Trial DetailsNCT05484687
Colonic Diseases, Colorectal Neoplasms
Nantong, Jiangsu, China
View Trial Details